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ABSTRACT 
 
Adult mesenchymal stem cells derived from adipose tissue (ASC) offer significant 
practical advantages over other types of stem cells (SC) for potential clinical 
applications, since they can be obtained from adult adipose tissue in large amounts, can 
be easily cultured and expanded with a very low risk for development of malignancies. 
We investigated in vitro the neuronal differentiation potential of human ASC with a 
chemical protocol and a prolonged two-step protocol, which included sphere formation 
and sequential culture in brain-derived neurotrophic factor (BDNF) and retinoic acid 
(RA). After 30 days, about 57% ASC show morphological, immunocytochemical and 
electrophysiological evidence of initial neuronal differentiation. In fact, ASC display 
elongated shape with protrusion of two or three cellular processes, selectively express 
nestin and neuronal molecules (including GABA-A receptor and tyroxine hydroxilase) 
in the absence of glial phenotypic markers. Differentiated cells show negative 
membrane potential (−60 mV), delayed rectifier potassium currents and TTX-sensitive 
sodium currents, but they are unable to generate action potential. Considering the low 
efficacy and the not-fully mature neuronal differentiation, we evaluated if ASC display 
a neuroprotective effect. Using the H2O2-stressed neuroblastoma model in vitro, we 
show that ASC increase cell availability (compared to fibroblasts) and protect against 
apoptosis. A possible mechanism involved could be the secretion of BDNF, as reported 
for human BM-MSC: in this regard, we indeed find high levels of BDNF in ASC-
condition medium. In addition to exert neuroprotection, soluble factors secreted by ASC 
promote neurite outgrowth, an additional mechanism that may favor neuroregeneration. 
In view of these results and their immunosuppressive action (Constantin et al, 2009), 
ASC may be a ready source of adult MSC to treat neurodegenerative diseases.  
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INTRODUCTION 
 
Stem cell therapy is a cellular approach that aims to induce the neuro-restorative 
process essential for facilitating recovery after a loss of function. Among the different 
application, neurological diseases are interesting potential target, since the adult nervous 
system has a limited regenerative capacity. 
A stem cell (SC) is an unspecialized cell that is able to self-renew indefinitely and 
can, under appropriate conditions, give rise to a wide range of mature cell types (Herzog 
et al, 2003). SC are defined by its ‘potential’ to generate more stem cells and 
differentiated daughters, rather than by its production of a SC and a differentiated 
daughter at each division, as classically defined as asymmetric cell division (Morrison 
and Kimble, 2006). 
Two types of SC, embryonic (ESC) and somatic, can be distinguished according to 
their origin and their potential of differentiation (Fig. 1). ESC are derived from the early 
blastocyst and the inner cell mass of the embryo and are able to differentiate into cell 
types of the three germ layers (Shuldiner et al, 2000). Somatic SC are isolated from 
foetal (after gastrulation) or adult tissues, and traditionally are programmed to only 
produce cell types that belong to the tissue which they originate from. Currently, 
somatic SC have been isolated from different organs or tissues, including bone marrow 
(Friedenstein et al, 1974), brain (Reynolds and Weiss, 1992), blood (Domen and 
Weissman, 1999), epidermis (Gandarillas and Watt, 1997) and skeletal muscle (Seale 
and Rudnicki, 2000). It was classically admitted that somatic SC support tissue 
homeostasis by replacing damaged cells. However, while a great number of organs or 
tissues contains somatic stem cells, it appears that these cells are mostly quiescent or 
weakly active and are unable to efficiently repair the damaged tissue. This is especially 
true for neural stem cells (NSC) which are found in the sub-ependymal layer of the 
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ventricular zone and the dentate gyrus of the hippocampus in adult mammals (Gage, 
2002), within a cellular niche (Rossi and Cattaneo, 2002). Those cells, while able to 
proliferate and differentiate in vitro into neurons, astrocytes and oligodendrocytes 
(McKay, 1997), do not guarantee a successful brain homeostasis after external insults. 
By contrast, adult BM is a potentially rich source of SC and contains two types of 
prototypical stem cell populations: hematopoietic stem cells (HSC) and mesenchymal 
stem cells (MSC). MSC, also referred as BM stromal cells, normally give rise to 
osteocytes, chondrocytes, adipocytes, during the whole life and thus guarantee 
homeostasis for these cell types and tissues. Moreover, such cells have been recently 
shown to display the ability to trans-differentiate, acquiring cell phenotype different 
from mesenchymal (Wislet-Gendebien et al, 2005a). 
ESC have seemed to be the most powerful tool for cell therapy in animal models, but 
several challenges need to be resolved before translate ESC application in humans. ESC 
are genetically and epigenetically unstable, and consequently human ESC lines can vary 
substantially with regard to differentiation potential. Furthermore, most differentiation 
procedures represent ‘run-through’ protocols, in which the cells are sequentially 
propagated in different media and growth factor conditions until they acquire the 
desired phenotype. Such approaches are prone to include undifferentiated ESC, which 
can result in formation of teratoma in the transplant recipients. A second risk factor for 
tumour formation is the protracted proliferation and differentiation times. This can lead 
to continuous cell proliferation after transplantation, resulting in neural overgrowth. 
Together, these concerns emphasise the need for more basic research into how to 
control proliferation and differentiation of ESC and their neural derivatives before these 
cells can be considered for clinical use. Despite the privileged immune status of the 
central nervous system (CNS), allogeneic grafts of stem cell-derived neurons and glia 
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remain susceptible to rejection; the establishment of ESC banks that contain ESC lines 
of different HLA haplotypes could overcome the problem (Koch et al, 2009). 
 
 
Fat
 
 
Figure 1. Sources of SC for therapeutic use. Pluripotent (namely embryonic) SC can be 
obtained from early stage embryos while somatic (or adult) SC – which are multipotent 
in nature and already partially committed into a certain types of cell lineages – can be 
virtually obtained from all tissue belonging to embryos, foetuses and adults. The 
therapeutic use of ESC is limited by the unlimited growth, the tumorigenic potential, 
and the undetermined differentiation. The therapeutic use of somatic (or adult) SC is 
restricted by the limited growth potential (from Pluchino et al, 2009). 
 
Regarding the neural application, NSC probably represents the first choice as cell 
population to use for neural replacement. Although NSC have been very useful for 
proof-of-principle in animal studies and pre-clinical trials, it is unlikely that they will 
ever be clinically useful. The primary reason for this is that the very small numbers of 
donors would not represent a sufficient pool to allow immunological matches. These 
donors collectively provide immunological matches for approximately 70% of the 
possible recipients. A bank of NSC to approach this level of matching ability would be 
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extremely laborious, expensive and time-consuming and it is unlikely to be ever created. 
It is possible, however, that NSC posses only a weak capacity to stimulate immune 
rejection and, when implanted into an immune-privileged site, such as the brain, might 
evade the immune system altogether (Schwartz, 2006). 
Thus, other somatic stem cells have been investigated, and growing interest has been 
paid to MSC because of their biological attractive features; in particular, they can be 
easily collected and extensively expanded in vitro and have the ability to seek out sites 
of tissue injury and repair the tissue by differentiating to replace injured cells or by 
creating an environment favorable for the repair of damaged tissue by endogenous cells 
(Izadpanah et al, 2005). Considering the different source of MSC, MSC derived from 
adipose tissue (ASC) are available in large quantities (hundreds of million cells per 
individual) and are easily isolated and can be cultured for several months in vitro with 
low levels of senescence (Zuk et al, 2001; Zuk et al, 2002). 
Several neurological diseases are characterized by (primary or secondary) neuro-
degeneration, combined with different degree of inflammation, as multiple sclerosis, 
stroke, Parkinson disease or traumatic injury. At present, therapy is mostly symptomatic 
and not restorative and the MSC therapy represents a powerful tool, considering their 
ability to immunomodulation, to support the brain parenchyma and their partial early 
trans-differentiation (Pluchino et al, 2009) (Fig. 2). 
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Figure 2. Whereas traditional approaches mainly used embryonic donor tissue, the 
current experimental choices include adult NSC, non-neural somatic stem cells and 
pluripotent sources such as induced pluripotent stem cells (iPSC). With regard to 
application, therapeutic benefits can occur through classic cell replacement, but also by 
transplant-mediated neuroprotective and immunomodulatory effects (from Koch et al, 
2009). 
 
1. MESENCHYMAL STEM CELLS (MSC) 
MSC are adult non HSC, originally isolated by BM (BM-MSC). The very early 
hypothesis about their existence goes back to 1867, when Cohnheim showed as the 
intravenous dye could be absorbed by fibroblast-like cells and found at a distant injured 
tissue. One century later, Friedenstein et al. cultured BM-MSC in adherent plates 
(Friedenstein et al, 1974). Such cells can give rise to colony similar to cartilage or bone. 
Later, with different culture conditions, BM-MSC have been reported to differentiate in 
adipocyte, osteoblast and chondrocyte (Pittenger et al, 1999; Benayahu et al, 1989; 
Colter et al, 2000; Jiang et al, 2002; Dennis and Charbord, 2002).   
Human BM-MSC are generally isolated from BM aspirate harvested from the 
superior iliac crest. Cells are cultured in basal medium such as Dulbecco’s modified 
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Eagle’s medium (DMEM) in the presence of 10% fetal bovine serum (FBS). BM-MSC 
in culture adhere to the tissue culture substrate, exhibiting a fibroblastic morphology, 
with large, flat body. When they reach the confluence they have fused morphology and 
they are no more able to differentiate in any kind of post-mitotic cell type. In vitro BM-
MSC proliferate fast (duplication time: 48-72 hrs), with no phenotypic modification till 
25 passages (Izadpanah et al, 2008).  
Despite increasing experimental and clinical interest in recent years, the 
understanding of MSC biology is not yet comprehensive. The absence of a consensual 
definition can make the results of MSC researches incomparable and it could be hinder 
progress in the field. 
Recently, the International Society for Cellular Therapy (ISCT) defines the minimal 
criteria to be met for cells to be considered human MSC (Dominici et al, 2006):  
1. adherence to plastic in standard culture conditions; 
2. phenotype positive (≥ 95%+): CD105, CD73, CD90; 
phenotype negative (≤ 2%+): CD45, CD34, CD14 or CD11b, CD79 α or CD19, 
and HLA-DR; 
3. in vitro differentiation: osteoblast, adipocyte, chondroblast (demonstrated by 
staining of in vitro cell culture). 
Such criteria show as the presumptive identification of the MSC remains mostly 
functional, lacking till now specific pattern of markers to prospectively and univocally 
isolate MSC. In fact, the basic question of how to define a MSC is still a point of 
discussion and controversy because of MSC are a heterogeneous population, and very 
recently some authors are trying to find new panel of markers (Roche et al, 2009) and to 
characterize the different subpopulations (Bühring et al, 2009). 
MSC, responding to their definition, are able to differentiate into to three 
mesodermal cells. The final proof of pluripotency is proven by clonal assay (Zuk et al, 
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2002; Guilak et al, 2006). Growing evidence has been showing as these cells are also 
able to change toward the neuro-ectodermal (Sanchez-Ramos et al, 2000; Korbling et al, 
2002; Grove et al, 2004) and endodermal lines (Petersen et al, 1999; Schwartz et al, 
2002; Jiang et al, 2002; Ianus et al, 2003). However, their capacity of mature 
differentiation and integration in the host tissue are not yet clear.  
MSC have been isolated by tissues other than BM, as periostioum (Nakahara et al, 
1990), trabecolar bone (Noth et al, 2002), synovium (De Bari et al, 2001), adipose 
tissue (Zuk et al, 2001), skeletal muscle (Jankovski et al, 2002), lung (Sabatini et al, 
2005), thymus, spleen, pancreas, kidney (Krampera et al, 2007; Da Silva Meirelles et 
al, 2006), peripheral blood (Roufosse et al, 2004), umbilical cord blood (Buzanska et al, 
2002) and placenta (Yen et al, 2005). All those cells are MSC, but show some 
differences related to proliferation and differentiation capacity (Kern et al, 2006; Peng 
et al, 2008).  
Focusing on adipose tissue, multipotent adherent cells have been isolated, and called 
with many terms, including adipocyte precursor cells (Hauner et al, 1989), 
preadipocytes, adipose-derived adult stem (ADAS) cells (Gimble and Guilak, 2003), 
adipose-derived stromal cells (Safford et al, 2002), adipose-derived adherent stromal 
cells (Katz et al, 2005), processed lipoaspirate cells (Zuk et al, 2001) and adipose-
derived stem cells (ASC) (Miranville et al, 2004). In accordance with a consensus 
reached by investigators attending the Second Annual International Fat Applied 
Technology Society meeting (2004, Pittsburgh, PA), we will refer to these cells as ASC.   
A typical harvest of adipose tissue can collect ~2 x 108 nucleated cells per 100 ml of 
lipoaspirate, yielding around 4 x 106 ASC; at variance, the adult BM aspirate volume is 
generally limited to no more than 40 ml and yields approximately 1.2 x 109 nucleated 
cells, containing approximately 2.4 x 104 ASC. Fat aspirate is less invasive method and 
contain higher number of MSC compared to BM aspirate (Strem et al, 2005). 
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Approximately 400,000 liposuction surgeries are performed in the U.S. each year and 
these procedures yield anywhere from 100 ml to >3 L of lipoaspirate tissue. This 
material is routinely discarded (Katz et al, 1999). Moreover, ASC possess larger rate of 
proliferation compared to BM-MSC (Peng et al, 2008).  
Although very similar to BM-MSC, ASC phenotypically differ regarding the 
expression of some adhesion molecules (ASC are intensively positive to CD54 and 
CD49d and weakly to CD106) and the lack of Stro-1 and genetically in around 1% 
genes (Gronthos et al, 2001; Zuk et al, 2002; De Ugarte et al, 2003; Romanov et al, 
2005; Katz et al, 2005; Lee et al, 2004; Kern et al, 2006). ASC show greater plasticity 
and ability to conversion from one cell type to another than BM-MSC (Dennis and 
Charbord, 2002) and the same immunosuppressive activity of BM-MSC (Yoo et al, 
2009).  
In brief, the advantages of using MSC in cell therapy, compared to ESC, include: 
a. the high availability, especially considering some cell sources, as adipose tissue; 
b. the easy culture method, with no need of feeder, and their ability to proliferate till  
25 passages with no signs of senescence (Izadpanah et al, 2008); 
c. the low immunogenicity, making them useful also in allo-transplant without 
immunosuppression (Javason et al, 2004; Barry and Murphy, 2004); 
d. no transformation in teratoma (Jiang et al, 2002; Dezawa et al, 2004; Tropel et al, 
2004); 
e. immunomodulant action, useful in inflammatory diseases as well as in graft-host 
versus disease prevention (Bartholomew et al, 2002; Krampera et al, 2003; Le 
Blanc et al, 2004; Zappia et al, 2005; Aggarwal and Pittinger, 2005; Le Blanc 
and Ringden, 2005); 
f. no ethical concern.  
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Moreover, as ESC, they can secrete trophic molecules that can support the damaged 
host tissue (Crigler et al, 2006; Zhao et al, 2004; Kang et al, 2003b); they can home 
into damaged tissues (Chamberlain et al, 2007) and can be transfected with therapeutic 
gene (Lee et al, 2003b; Zhao et al, 2004). 
All these features make ASC the ideal candidate for very different neurological 
diseases associated with degeneration and inflammation. Anyway, the complexity of the 
mechanisms involved in survival, differentiation and immunomodulation is not yet 
completely understood. The most vivid controversy is about the role of MSC in tumor: 
some works report their anti-tumoral effect, contrasting with other evidence that show 
pro-tumor activity, especially related to their pro-angiogenic and trophic properties 
(Bexell et al, 2009; Sasportas et al, 2009; Karnoub et al, 2007). The ASC experimental 
application in tumor is much more limited (Muehlberg et al, 2009; Sun et al, 2009; 
Cousin et al, 2009; Yu et al, 2008). The MSC ability of homing is unique, and make 
them useful looking forward gene-therapy also in the most common adult CNS tumor, 
the glioma (Nakamizo et al, 2005). Concerning ASC, they have been used with success 
as cellular vehicles of prodrug-activating enzymes in models of glioblastoma, 
melanoma and prostate cancer (Matuskova et al, 2010; Kucerva et al, 2008; Cavarretta 
et al, 2010). 
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2. NEURAL MSC DIFFERENTIATION 
‘From marrow to brain’ titled the first article that reported as transplanted BM cells 
have been found in brain, expressing neural markers (Brazelton et al, 2000; Mezey et al, 
2000), and later Cogle et al. described similar data in human (Cogle et al, 2004), 
showing as BM elements are able to cross the blood brain barrier and to exhibit a 
neural-like phenotype. These phenomena, however, were not evident in other studies 
(Castro et al, 2002; Wagers et al, 2002). Contemporaneously two pioneering works 
reported early trans-differentiation of MSC into neurons in vitro (Woodbury et al, 2000; 
Sanchez-Ramos et al, 2000). Such evidence gave rise to great interest, and in this 
decade several authors have studied the ability of MSC to differentiate into neural cells 
(Abouelfetouh et al, 2004, Deng et al, 2001, Kim et al, 2002, Kohyama et al, 2001; Qian 
and Saltzman, 2004; Woodbury et al, 2002).  
The ability to manipulate MSC in vitro serves two logical purposes. First, pre-
differentiation of MSC into more restricted neural cell types could enhance their ability 
to anatomically and functionally integrate into particular parts of the brain, with 
presumably higher efficacy in ameliorating lesions. Second, differentiated neural cells 
(especially when they become post-mitotic) are generally considered to have a lower 
chance of the eventually malignant transformation as compared to actively dividing 
precursors. 
The studies attempting to differentiate MSC in vitro into neurons have used different 
approaches. Some involved rather simple chemicals, others used growth factor 
cocktails. Still others have more elaborate strategies involving transgenic expression of 
particular genes or co-culture. It should be kept in mind that MSC are by nature a 
heterogeneous population of cells with sub-populations with different morphology, 
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proliferative capacity and multipotency, and then different ability to trans-differentiate 
(Chen et al, 2006; Bühring et al, 2009). 
The first approaches using chemical agents as, for example, β mercaptoetanol 
(BME), butylated hydroxyanisole (BHA), isobutylmethylxanthine (IBMX), make MSC 
modify into cells with contracted soma and elongated processes, staining for neural 
markers. Reports using different species and source of MSC described the morphology 
suggestive of neuron and the expression of neural markers (Woodbury et al, 2000; 
Woodbury et al, 2002; Deng et al, 2001; Rismachi et al, 2003; Yamaguchi et al, 2006). 
But some authors hypothesized that such phenomenon may be caused, or at least 
accompanied, by cellular events other than differentiation. First, the morphological 
changes did not come with clear observations of neurite growth cones, and were 
associated with a high degree of cell death. Second, and more important, this apparent 
trans-differentiation occurred in a seemingly unrealistic time frame of hours, compared 
with the days required for MSC to differentiate into cells of mesodermal origin, 
suspecting an underlying disruption of the actin cytoskeleton. Treatment with low pH or 
high salt produced similar morphological changes, which could also be observed when 
other cell types, such as fibroblasts, were subjected to BHA/DMSO treatment (Lu et al, 
2004; Neuhuber et al, 2004; Bertani et al, 2005). Conversely, a plethora of cell stress 
such as EDTA, cytocalasin D and detergents could also elicit similar changes in MSC. 
Although the expression of classical neuronal markers (Neu-N and the 200-kDa 
neurofilament) is judged to be increased by immunostaining, these appeared to be 
aberrantly localized in the cell, and elevation of protein levels could not be confirmed 
by reverse transcription-polymerase chain reaction (RT-PCR) and Western blot. 
Another point to note is that MSC appeared to already express varying levels of neural 
and astrocytic markers, and inhibition of protein synthesis with cycloheximide did not 
prevent cells from adopting neuron-like morphology after chemical induction. This 
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apparent lack of a need for transcriptional or translational change undermined the 
suspected trans-differentiation nature of the observed changes and reinforced the doubts 
on the effective neural differentiation. 
More convincing evidence (morphological and phenotypical) of prolonged mature 
neural differentiation can be obtained using growth factors and signalling agents as 
brain-derived neurontrophic factor (BDNF), basal fibroblast growth factor (bFGF), 
FGF-8, nerve growth factor (NGF), ciliary neurotrophic factor (CNTF), cAMP, dibutiril 
cAMP (dbcAMP), retinoic acid (RA) or forskolin (Sanchez-Ramos et al, 2000; Dezawa 
et al, 2004; Kohyama et al, 2001; Tonderau et al, 2004; Long et al, 2005).  
Specific protocol using growth factors has been translated from the NSC culture 
method. NSC are traditionally grown in EGF and bFGF (the so-called neurosphere 
media), forming floating aggregation called neurosphere (Reynolds and Weiss, 1992). In 
such milieu, NSC can highly proliferate. Neurospheres are variably constituted by SC 
(10-50%), progenitors and differentiated cells; and represent the optimal solution of 
environmental adaptation in vitro conditions (Bez et al, 2003). Culturing the MSC in the 
neurosphere-media represents a potential way to get neural progenitor cell-like in vitro 
(Bunnell et al, 2006). BM-MSC can form neurosphere-like in vitro, and then they can 
be induced by different agents (RA, dbcAMP, bFGF or BDNF) to differentiate in the 
neural lineage, with no selective phenotype. Wislet-Gendebiens et al. show that MSC 
neurosphere-like co-culturing with embryonic NSC express selectively astrocytic 
markers (Wislet-Gendebiens et al, 2003). Hermann et al. report more exhaustive results: 
human BM-MSC can form neurosphere-like and later, induced by N2, RA e BDNF, 
they can acquire mostly neuronal phenotype and produce dopamine. Such modifications 
do not happen without the neurosphere-step. Unfortunately technical limitations make 
no possible to get functional data (Hermann et al, 2004). 
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Independently from the factors inducing the differentiation, the neuron is a polarized, 
post-mitotic cell, with an axon and multiple dendrites, able to give rise to the action 
potential and to communicate through synapses with the others (Reh, 2002), and the 
electrophysiological data should support any type of ‘differentiation’. Recently, some 
preliminary promising data have been reported. BM-MSC treated with growth factor 
exhibit negative membrane potential and very low potassium and sodium currents 
(Kohyama et al, 2001; Dezawa et al, 2004; Hung et al, 2002; Egusa et al, 2005). More 
relevant results have been obtained transfected MSC with BDNF (Zhao et al, 2004) or 
Notch (Dezawa et al, 2004) or after co-culture with fetal murine astocytes (Jiang et al, 
2003) or cerebellar granula (Wislet-Gendebien et al, 2005b). Among these works, only 
Dezawa et al. (Dezawa et al, 2004) use human cells. 
Considering how complicated and long is the embryonic CNS development, it can be 
easily comprehensible why these studies achieved only an early neuron-cells in vitro 
(Carleton et al, 2003).  
Among MSC, interest is growing about neural differentiation potential of ASC. 
Compared to BM-MSC, ASC show a higher tendency to differentiate into the neural 
line: they produce larger amount of BDNF and react to NB and B27 media expressing 
higher level of nestin and MAP-2; moreover, in basal condition they express, low levels 
of nestin, Neu-N, Ca++ α1 channel, sinapsyn I (Kang et al, 2003a; Kang et al, 2004; 
Ashjian et al, 2003; Safford et al, 2004; Yang et al, 2004). 
Safford and collegues were the first to induce neural differentiation by human ASC 
in vitro, by treatment with EGF and bFGF, followed by BHA and forskolin: the cells 
readily change in morphology and phenotype, expressing at the same time early and 
some mature neuronal (nestin, Neu-N), glial markers (GFAP) and neurotransmettitor 
receptors (glutamate and GABA receptors) and lacking the expression of tyrosine 
hydroxylase (TH), dopamine-decarboxylase and 5-hydroxytryptophan. Moreover, there 
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was a massive cell death at the 5th day of culture. Such differentiation was unspecific, 
incomplete and short-lasting (Safford et al, 2002; Safford et al, 2004). Other chemical 
treatments with BME induced more selective neuronal morphology and phenotype, with 
no data about the functional properties (Zuk et al, 2002; Tholpady et al, 2003; Romanov 
et al, 2005). Only Ashjian et al. in vitro showed K+ outward rectified currents in 
modified ASC exposed to IBMX and indomethacin for 14 days: this data was not 
selective for neuronal differentiation (Ashjian et al, 2003). The ability of ASC to form 
neurosphere-like is not well studied. ASC treated by NB and B27 after neurosphere-step 
express at the same time neuronal and glial markers (nestin, MAP-2, GFAP); the 
percentage of differentiated cells increases after BDNF (Kang et al, 2004).  
In vivo MSC have been shown to generate both migratory neurons and guiding radial 
glia and to specifically differentiate after intra-ventricular injection in embryonic 
murine brain (Munoz-Elias et al, 2004). In animal disease models the data about neural 
potential are largely debated; in this regard, we and other authors have not shown in 
vivo trans-differentiation (Constantin et al, 2009; Gerdoni et al, 2007; Kim et al, 2007; 
Cova et al, 2010), whereas others report early neural differentiation, although 
unselective, immature and not sustained by direct functional data (Li et al, 2001; Chen 
et al, 2001a; Chen et al, 2001b; Zhao et al, 2002; Hess et al, 2002; Hofstetter et al, 
2002; Lee et al, 2003a; Kassis et al, 2008). In addition, some groups dispute the 
potential fusion of MSC with the host cells, that can misinterpret the results (Spees et al, 
2003; Terada et al, 2002). At the other side, it is still contrasting if in vitro pre-neural 
differentiation of MSC can be advantageous to the long-lasting effect of MSC transplant 
(Parr et al, 2007; Zhang et al, 2009). 
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3. MSC NEUROPROTECTION 
Although the neuroprotective effects of MSC may result from their ability to replace 
the diseased or damaged neurons via cellular trans-differentiation, this specific pathway 
is probably very limited, although the functional improvement in animal model can be 
dramatic after MSC transplant (Hofstetter et al, 2002; Lanza et al, 2005; Constantin et 
al, 2009). In addition to the bystander effects reported mainly in the experimental 
autoimmune encephalomyelitis (EAE) model (Gerdoni et al, 2007; Constantin et al, 
2009), other factors have recently been hypothesized, such as their trophic support and 
antioxidant potential. 
Neurotrophins are a family of proteins that promote the survival, development and 
function of neurons. Among others, NGF and BDNF inhibit death-inducing pathways 
and also activate a variety of cell survival pathways of neuron and oligodendrocyte 
(Gravel et al, 1997; Thoenen, 1995); bFGF moreover promotes angiogenesis (Meijs et 
al, 2004). They are endogenously synthesized in the CNS, and they can be unbalanced 
in several neurological diseases. The administration of neurotrophins has been proposed 
as potential approach to the therapy of neural disorders such as Parkinson, Alzheimer, 
Huntington diseases, stroke and spinal cord injury (Gash et al, 1996; Nagahara et al, 
2009; Jin et al, 2005; Schabitz et al, 2000; Cheng et al, 2002). However, issues relating 
to compound delivery and potential side effects have limited the clinical application of 
this treatment strategy. 
Indeed, MSC are able to produce important neurotrophic factors that support 
neuronal cell survival and promote nerve fiber regeneration at the sites of injury. BM-
MSC are known to produce NGF (Labouyrie et al, 1999; Garcia et al, 2004; Jiang et 
al, 2010; Crigler et al, 2006), BDNF (Labouyrie et al, 1999; Chen et al, 2002; Crigler 
et al, 2006; Neuhuber et al, 2005; Jiang et al, 2010), GDNF (Garcia et al, 2004; Jiang 
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et al, 2010) and bFGF (Mahmood et al, 2004). Regarding ASC, human type can secrete 
BDNF, NGF (Qian et al, 2009 epub), vascular endothelial growth factor (VEGF), 
hepatocyte growth factor (HGF), insulin growth factor 1 (IGF1) (Rehman et al, 2004; 
Wang et al, 2006). BDNF, HGF, IGF, bFGF and PDGF can be secreted by rat ASC 
(Peng et al, 2008; Wei et al, 2009a; Wei et al, 2009b) and BDNF, NGF, bFGF and 
PDGF by murine ASC (Costantin et al, 2009; Zhang et al, 2009). Interestingly, the 
growth factor levels change related to MSC passages and to the considered cell sub-
population (Crigler et al, 2006; Wilkins et al, 2009).  
Neural-induced MSC display remarkably decreased levels of neurotrophins, 
regardless the MSC source, including rat BM-MSC (Jiang et al, 2010), human ASC 
(Qian et al, 2010) and human umbilical cord MSC (Koh et al, 2008). Such data in vitro 
could reflect the effect of artificial manipulation as well as the physiological aging, 
exhibiting how highly dynamic is the neurotrophin expression profile. Thus, non-
induced MSC provide a natural carrier for neurotrophins.  
The homeostasis and regular function of the neuron is guaranteed from the niche 
which supplies, besides growth factors, the opportune conditions to balance the 
oxidative stress. Regardless of the etiology, a component of oxidative stress is present in 
all neurodegenerative disorders, although is not yet clear if the oxidative stress is the 
consequence or the early event of the disease. Moreover, nitric oxide (NO) is a common 
second messenger in inflammatory signaling, and reactive nitroxide species (RNS) as 
well as Reactive Oxygen Species (ROS) are capable of both oxidation and nitration 
chemistries. Thus the oxidative stress is involved, besides to degenerative diseases, in 
neuro-inflammatory pathologies, as multiple sclerosis (Sayre et al, 2008). The relevance 
of oxidative stress contribution to the progression of many neurodegenerative disorders 
has generated an interest in the potential use of oxygen and nitrogen radical scavengers 
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and their natural biological counterparts for protecting cells and tissues from oxidative 
damage (Prokai et al, 2003; Sancivez et al, 2006). 
Recently MSC has been shown to exert antioxidant effect, although the underlying 
mechanisms are largely unknown. Uccelli and coworkers reported that human BM-
MSC decrease the expression of non-enzymatic and enzymatic antioxidants in H2O2-
stressed neuroblastoma model in vitro, as well as in EAE (Lanza et al, 2009). 
Human BM-MSC have been shown to be able to protect cerebellar neurons in vitro 
via cell-cell contact and/or secretion of soluble factors (among others, SOD3) after 
trophic deprivation and NO exposure (Kemp et al, 2009 epub). Murine BM-MSC can 
decrease glutamate-induced apoptosis in neuron (Hokari et al, 2008). 
As BM-MSC protect versus apoptosis (Zhao et al, 2004), very recently Wei et al. 
show as rat ASC protect neurons against low potassium or serum free-induced 
apoptosis, reducing caspase 3+ cells and Akt phosphorilation (Wei et al, 2009b). It is 
largely unclear if and how MSC can resist to the stress condition that damages neuron. 
Oxidative stress does not activate caspase 8 and 9 in MSC (Szegezdi et al, 2008 epub). 
The combination of growth factors and antioxidant molecules produced by MSC can 
partially explain some in vivo results: BM-MSC transplant into the injured spinal cord 
promotes tissue sparing, which is evidenced by smaller cavities and preserved host 
white matter (Akiyama et al, 2002; Ankeny et al, 2004; Ohta et al, 2004; Zhang et al, 
2009), decrease the ischemic volume in stroke (Zhao et al, 2004; Liao et al, 2009; Koh 
et al, 2009) and reduce axonal loss in EAE (Zappia et al, 2005; Kassis et al, 2008; 
Costantin et al, 2009). More interesting, MSC promoted endogenous neural progenitor 
cell proliferation in chronic EAE (Constantin et al, 2009), stroke (Yoo et al, 2008) or 
brain injury (Mahmood et al, 2004). Some authors selectively inhibit growth factor in 
vitro or in vivo (in animal disease model treated with MSC) and show the decrement of 
the beneficial effect of MSC treatment (Wilkins et al, 2009; Koh et al, 2008), sustaining 
21 
 
the role of growth factors. At the other side, other studies in vivo reveal an increase of 
BDNF in the MSC-treated group compared to sham (Nomura et al, 2005; Zhang et al, 
2009) and ASC-Condition Media (ASC-CM) improve stroke (Wei et al, 2009a).  
Thus, it is likely that the mechanisms underlying the neuro-protective effect of MSC 
transplant are related to the cell ability to produce and secrete factors that either arrest 
and/or prevent the onset of cell-destructive events.  
The use of ASC in CNS disease model is very limited: our group very recently has 
shown how ASC can exert immunomodulation and neuro-protection in EAE 
(Constantin et al, 2009); three others used ASC in stroke model (Kang et al, 2003a; 
Kim et al, 2007; Wei et al, 2009a); Huntington disease model and spinal cord injury 
have been moreover recently investigated (Lee et al, 2009; Zhang et al, 2009). 
Intravenous administration of ASC in chronic established EAE significantly ameliorates 
the disease course and reduces both demyelination and axonal loss, increases number of 
endogenous oligodendrocyte progenitors and induce a Th2-type cytokine shift in T cells 
(Constantin et al, 2009); intraventricular injection of ASC ameliorate clinical outcome: 
partially reach the ischemic area and differentiate in neural line (Kang et al, 2003a); 
also ASC-CM injection is beneficial for stroke, reducing the secondary brain atrophy 
and the apoptotic cells (Wei et al, 2009a). In all these studies the role of growth factors 
synthesized by ASC is stressed. 
Therapeutic applications of MSC in human neurological diseases are still 
preliminary: the first results regard methacromatic leukodystrophy and Hurler syndrome 
(Koç et al, 2002), stroke (Bang et al, 2005) and amyotrophic lateral sclerosis (Mazzini et 
al, 2006; Mazzini et al, 2010) and trials in humans are ongoing on intrathecal or 
intravenous BM-MSC in multiple sclerosis (NCT00781872, NCT00395200), 
intravenous BM-MSC in stroke (NCT00875654) and stereotactic application in PD 
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(NCT00976430). Such clinical trials are mostly studying the safe profile, meanwhile 
experimental laboratory studies are deeply investigating the mechanisms involved. 
 
This study aims to further investigate the potential neuroprotective and neural-
regenerative effect of ASC. These cells have several advantages over ESC and NSC, 
including lack of ethical controversy, immunosuppressive effects demonstrated in 
clinical settings (Le Blanc et al, 2004; Ringden et al, 2006), and readily availability 
through very low invasive procedure. 
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AIMS OF THE PROJECT 
 
ASC are adult MSC, easily available and safe. Considering that MSC has been 
shown to have neural potential and trophic function, we evaluated in vitro the ability of 
ASC to differentiate in neuron and their neuroprotective action against oxidative stress. 
The research includes: 
a. chemical neural induction: morphological and phenotypic evaluation, 
b. two-step neuronal protocol, including neurosphere-formation and RA and BDNF 
long-lasting induction: morphological, phenotypic and electrophysiological evaluation; 
c. Neuroprotective effect of ASC-CM: proliferation and apoptosis assay considering 
the effect of ASC-CM on H2O2-stressed neuroblastoma line in vitro, as compared to 
fibroblast effect. 
 
The adult cells should represent the powerful future therapeutic tool for the 
neurological diseases, regarding their multiple mechanisms of action, including the 
trans-differentiation potential, the antioxidant and trophic activity and the 
immunomodulant action that could overcome either the inflammatory and the 
degenerative component of the disease. 
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MATERIAL AND METHODS 
 
CELL CULTURE 
Human fibroblasts were collected from diagnostic muscle biopsy after informed 
consent, and grown in 10% FBS and DMEM (Gibco, Milan, Italy). SH-SY5Y human 
neuroblastoma line (courtesy gift from dr. Della Bianca) was cultured in monolayer in 
Royal Park Memorial Institute (RPMI)-1640 medium supplemented with 10% FBS. The 
cell cultures were saved at 37°C in a humidified atmosphere of 5% CO2/95% air. 
 
ISOLATION AND CULTURE OF HUMAN ASC 
Human ASC were obtained from 40 ml lipoaspirate samples of abdominal fat from 
female donors after informed consent (Katz et al, 2005). Extracellular matrix is digested 
at 37°C in Hank’s balanced salt solution with 1 mg/ml collagenase type I. Cells are then 
maintained in basal medium (20% FBS/DMEM) and cells are centrifuged at 1,200 g for 
10 minutes; the pellet is then resuspended in 160 mM NH4Cl to lyse contaminating red 
blood cells and filtered through a 70-µm nylon mesh. The cells are cultured at 30 x 106 
cells/cm2 in 25 cm2 flasks in DMEM with high glucose concentration, GLUTAMAX 
ITM, FBS, penicillin and streptomycin (all from Gibco). After 72 hrs, non-adherent 
cells are removed. When 70-80% confluent, adherent cells are trypsinized, harvested 
and expanded in larger flasks. A homogenous cell population is obtained after 3 to 5 
weeks of culture. All the experiments are performed on cells at passages 7 to 16.  
Human ASC were characterized by the expression of CD105 (endoglin), CD73, 
CD29, CD44, CD90 class I HLA and lack of haematopoietic (CD45, CD14, CD34) and 
endothelial (CD31) markers. All the above monoclonal antibodies (mAb) are purchased 
from Pharmingen/Becton Dickinson. For the immunophenotypic analysis, ASC are 
detached using trypsin/EDTA, washed with PBS and resuspended at 106 cells/ml. Cell 
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suspension is incubated in 15% FBS, followed by incubation with the specific mAb for 
30 minutes. At least 10,000 events are analyzed by flow cytometry (FACScalibur, 
Becton Dickinson) using Cell Quest software. 
 
MESENCHYMAL DIFFERENTIATION OF ASC  
Multilineage differentiation potential was assessed by testing the ability of ASC to 
differentiate into adipocytes, osteoblasts, and chondrocytes, as previously described 
(Pittenger et al, 1999). Briefly, adipocyte differentiation is achieved after 3-week 
culture of ASC with adipogenic medium, containing 10-6 M dexamethasone, 10 µg/ml 
insulin and 100 µg/ml 3-isobutyl-1-methylxantine (Sigma Aldrich). Osteoblast 
differentiation is achieved after 3-week culture with osteogenic medium containing 10-7 
M dexamethasone, 50 µg/ml ascorbic acid and 10 mM β-glycerophosphate (Sigma 
Aldrich). Chondrocyte differentiation is achieved after 3-week culture with 
chondrogenic medium, containing 10-7 M dexamethasone, 10 ng/ml TGF–µ1, 50 µg/ml 
ascorbic acid, 40 µg/ml proline (Sigma Aldrich) and ITS+ Premix (BD Biosciences). 
Oil-red-O, von Kossa and toluidine blue dyes are employed to identify adipocytes, 
osteoblasts and chondrocytes, respectively.  
 
NEURAL DIFFERENTIATION: CHEMICAL PROTOCOL 
Chemical neural induction was performed according to a modified protocol from 
Woodbury et al. (Woodbury et al, 2000). Briefly, basal medium is replaced with DMEM 
and FBS supplemented with 5 ng/ml bFGF (Sigma Aldrich) for 24 hrs; after this pre-
induction, cells are washed with PBS and induction medium including DMEM with N2 
supplement, butylated hydroxyanisole (BHA), KCl, valproic acid and forskolin (all 
from Sigma Aldrich) is added for 2 to 16 hrs. Cells are either fixed for 
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immunocytochemistry or transferred to basal medium for other 7 days, and then assess 
their morphology and phenotype. 
 
NEURAL DIFFERENTIATION: PROLONGED NEURONAL DIFFERENTIATION 
PROTOCOL 
Neuronal differentiation was induced by culturing ASC for 72-96 hrs in serum-free 
medium with 20 ng/ml bFGF and 20 ng/ml human epithelial growth factor (hEGF) (all 
from Peprotech), with the formation of floating bodies. Such spheres are then subjected 
to immunocytochemistry or dissociated and seeded on poly-L-lysinated coverslips 
(Sigma Aldrich) at 1,000/cm2 in DMEM, 2% FBS, 10 ng/mL BDNF (Peprotech) and 
0.75 mM all-trans RA (Sigma Aldrich). Medium is replaced every 5-6 days up to 30 
days, when the cells are subjected to morphological, immunocytochemical and 
electrophysiological analysis to assess the presence of neuronal features. Alternatively, 
neuronal induction medium is replaced with basal medium for 7 days and the stability of 
the neuronal features is assessed as above. 
 
PREPARATION OF FIBROBLAST- AND ASC-CONDITION MEDIA (CM) 
ASC-CM was collected after culturing ASC in sub-confluent monolayer for 48 hrs. 
CM is used pure or diluted 1:1. As control, we use basal media or fibroblast-CM, 
harvested by sub-confluent cultures. The preparation of ASC-CM and fibroblast-CM for 
the ELISA assay was as followed: 1 x 105 cells are grown in basal condition for 24 hrs 
in 24-well plate, the supernatants are harvested, centrifuged for 10 min to remove cell 
debris and stored at -80 °C. 
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NEUROBLASTOMA MODEL AND THE OXIDATIVE STRESS MODEL 
Neuroblastoma cell lines are a classical model system to study neuronal responses to 
different type of insults (Sancivens et al, 2006). SH-SY5Y are cultured in 24-well 
dishes, containing 1 ml of ASC-CM, fibroblast-CM or basal medium. After 48 hrs, 
neuroblastoma cells are fixed and stained with βIII tubulin (see below). H2O2 is diluted 
with culture medium at 100 µM concentration immediately before use. SH-SY5Y, ASC 
or fibroblast are exposed to H2O2 stress. SH-SY5Y are exposed to H2O2 in ASC-CM, 
compared to fibroblast-CM and/or basal media. Cells treated are evaluated for 
proliferation or processed for immunofluorescence (caspase 3) (see below).  
 
PROLIFERATION ASSAY 
Cells are seeded in 96-well plate and exposed to 100 and 200 µM H2O2 at 37 °C and 
5% CO2. The oxidative stress is performed in 10% FBS/DMEM (control) or 1:1 ASC-
CM, for 24 hrs. Then, 10 µl Reagent 1 is added to each well, incubated overnight. The 
day after Reagent 2 is added and within 20 minutes the plate is read at 655 nm. 
 
IMMUNOCYTOCHEMISTRY  
ASC cellular morphology was evaluated at light microscope after fixation in 4% 
paraformaldehyde and hematoxilin staining or at scanning electron microscope (DSM 
950, Zeiss, Germany) after sequential fixation in glutaraldehyde and 1% osmium 
tetroxide for 15 minutes, dehydration and final fixation with colloidal silver and gold. 
The immunophenotype of ASC was evaluated with antibodies directed against the 
mesenchymal marker CD105 (1:500, Caltag Laboratories, Burlingame, CA); the 
neuronal markers microtubule-associated protein 2 (MAP-2) and neuronal nuclear 
antigen (Neu-N) (both 1:1,000); nestin (1:200), a protein of intermediate filament 
expressed by NSC; the oligodendroglial marker Gal-C (1:100) (all from Chemicon Inc., 
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Temecula, CA), the astrocytic markers S-100 (1:5,000) and glial fibrillary acidic protein 
(GFAP) (1:10,000, Dako); the Schwann cell marker PMP-22 (1:5,000; Chemicon); 
tyroxine hydroxilase (TH), an enzyme of catecholaminergic neurons (1:2,000, Santa 
Cruz Biotechnolgy, Inc., Santa Cruz, USA); sodium channel (1:800), α subunit of 
GABA-A receptor (1:400; Sigma). After washing, appropriate biotynilated secondary 
antibody and ABC amplification kit (Vector Laboratories, Burlingame, CA) are added 
and the reaction visualized with diaminobenzidine. Negative control includes the 
omission of primary antibodies. Experiments are performed in triplicate and the 
percentage of positive cells is blindly calculated. To determine the mitotic activity of 
ASC before and at the 28th day of the neuronal induction protocol, cells are exposed to 
10 µM BrdU (Sigma Aldrich) for 4 hrs, fixed with cold ethanol for 20 minutes, treated 
with 2N HCl and then with 0.1M NaBo, pH 9. Double immunofluorescence is 
performed for MAP-2 and BrdU, whose signals are detected with secondary antibodies 
conjugated respectively with Streptavidine Texas Red (Vector) and fluorescein 
isothiocyanate (FITC) (both from Boehringer). Nuclei are stained with 50 µg/ml DAPI 
(Sigma). Cells are observed at the fluorescent microscope (Zeiss MC80) and the rate of 
mitotic activity is calculated dividing the number of BrdU+/MAP-2+ cells and that of 
BrdU+/MAP-2- elements by the total DAPI+ cells. 
SH-SY5Y are fixed in 4% paraformaldehyde, and then processed for the 
cytochemistry to evaluate the neurite outgrowth evidenced by anti-βIII tubulin mAb 
(1:300, Chemicon). The antibodies are incubated overnight and then revealed with the 
secondary fluorescent secondary antibody FITC. DAPI is used as nuclear marker. Cells 
are observed at the fluorescent microscope: to determine the mean number of neuritis 
we count an average of one hundred SH-SY5Y cell bodies for each condition in each 
experiment. The apoptotic activity is investigated by the immunofluorescence using the 
caspase 3 antibody (1:400, Cell Signaling Technology) and the secondary Ab FITC. 
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Nuclei are stained with DAPI. Stress-induced apoptosis are calculated as ratio between 
caspase 3+ during H2O2 and caspase 3+ in basal condition. 
 
ELECTROPHYSIOLOGY 
Coverslips with ASC are placed in the recording chamber (1 cm3 volume) and 
mounted on Olympus BX50WI microscope. The cells are perfused at the rate of 2 
ml/min with artificial cerebro-spinal fluid with the following composition (mM): 125 
NaCl, 2.5 KCl, 26 NaHCO3, 1.25 NaH2PO4, 2 CaCl2, 1 MgCl2, and 15 glucose (all from 
Sigma). Saline is continuously bubbled with 95% O2/5% CO2; the osmolarity is 
adjusted at 305 mOsm with glucose. Cells are exposed to tetrodotoxin (TTX, Alomone, 
Jerusalem, Israel), tetraethylammonium (TEA), glutamate or GABA (all from Sigma 
Aldrich). The tight-seal whole-cell recording technique is used. Borosilicate glass 
pipettes (OD 1.5 mm; ID 0.86 mm; Hilgenberg, Malsfeld, Germany) with internal 
filament are adopted for recordings. The pipettes have a tip resistance ranging from 4 to 
6 MΩ when fill with these solutions. Seal resistance is always greater than 2 GΩ. The 
solution used for the recording pipette-filling solution contains (mM) 120 KCl, 10 
NaCl, 2 MgCl2, 0.5 CaCl2, 5 EGTA, 10 HEPES, 2 Na-ATP, 10 glucose; the osmolarity 
is adjusted at 295 mOsm with glucose, and pH at 7.2 with KOH. Membrane currents are 
recorded and acquired with Axopatch 200A amplifier (Molecular Devices, Sunnyvale, 
CA). The series resistance is around 15 MΩ; 60-70% compensation of the series 
resistance is routinely used. Data acquisition is performed by a Pentium-based computer 
using 12 bit A/D-D/A converters (Digidata 1200B; Molecular Devices). 
Prior to acquisition, the signals are filtered at half the sampling frequency by a 
lowpass 4-pole Bessel filter and digitized with sample times ranging from 10 to 100 µs. 
Off-line analysis is performed using version 10.1 of pClamp (Molecular Devices). Data 
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are expressed as mean + SEM and are statistically analyzed using Origin 7.5 software 
(OriginLab, Northampton, MA). 
 
ELISA ASSAYS FOR GROWTH FACTORS 
To determine the production of bFGF, BDNF, CNTF and PDGF-AB by ASC and 
fibroblasts their supernatants were analyzed by Quantikine® ELISA Immunoassay 
(R&D, Systems, Inc.), following the manufacturer’s instructions. Samples are added in 
96-well pre-coated plates and incubated for 2 hrs at RT. After washing, a specific 
polyclonal antibody followed by substrate solution is added and the colour development 
is measured at 450 nm (BioRad Microplate Reader). The concentration of growth 
factors is calculated using the standard curve. 
 
STATISTICAL ANALYSIS 
The results obtained by immunocytochemistry and electrophysiology in basal 
conditions and after neuronal induction are evaluated by Student’s t-test and the 
difference is considered statistically significant when p<0.05.  
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RESULTS 
 
BASAL ASC MORPHOLOGY AND PHENOTYPE 
In basal conditions, ASC express CD105, CD73, CD29, CD44, CD90, CD106, lack 
of hematopoietic (CD45, CD14, CD11c, CD123 and CD34) and endothelial cell 
markers (CD31), and display the ability to differentiate into adipocytes, osteoblasts and 
chondrocytes (Fig. 3).  
 
  
Figure 3. Multilineage differentiation of ASC. ASC are cultured for 14 days in flasks 
with adipogenic, osteogenic or chondrogenic media. Then cells are stained with Oil-red-
O (A), von Kossa (B), and toluidine blue (C) methods, respectively, which confirm their 
multi-lineage potential. The figure shows a representative picture of three different 
experiments. Scale bar: 10 µm. 
 
ASC in basal conditions form a monolayer of large and flat cells, assuming spindle-
shaped morphology at confluence (Figs. 4A, B). As far as molecules of the neural 
lineage are concerned, ASC express in basal conditions low levels of GFAP and PMP-
22 (Figs. 4C, D), and MAP-2 (not shown) and are negative for the other investigated 
markers (Neu-N, PSA-NCAM, nestin, GFAP, S-100 and Gal-C). 
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NEURAL DIFFERENTIATION: CHEMICAL INDUCTION 
After exposure to neural induction medium, ASC exhibit very rapid morphological 
changes: most cells retract their cytoplasm, forming spherical cell body, emit cellular 
protrusions and completely stop to proliferate, as compared to ASC in basal conditions 
(13.9 ± 3.1% of ASC incorporating BrdU, 3 experiments). At the end of this process, we 
can identify three morphologically distinct subsets of ASC: 50-70% of ASC appears as 
sharp, elongated bi- or tripolar  cells with primary and secondary processes (Figs. 4E-
G), morphologically reminiscent of neurons or astrocytes and shows intense expression 
of PMP-22 (Fig. 4E1), GFAP (Fig. 4F1), Neu-N (Fig. 4G1), PSA-NCAM, nestin, S-
100, MAP-2 and Gal-C (not shown); irrelevant mouse or rabbit IgG give no staining 
(Fig. 4K). The second population (about 15%) is characterized by elements with 
irregular shape and short, multibranched processes, morphologically similar to cells of 
the oligodendroglial lineage (Fig. 4H), and selectively express Gal-C (Fig. 4H1). The 
last population (15-20%) is similar to ASC in basal conditions, i.e., remains 
undifferentiated and does not up-regulate any neural markers. Irrespective of the 
morphological changes, all ASC retain CD105 expression (data not shown). These 
events start after 1 hr and reach their peak within around 2 hrs. With longer culture 
times, signs of cell toxicity are observed, with retraction of cell processes, detachment 
from plastic and eventually apoptosis of virtually all ASC.  
The neural differentiation protocol induces a transient differentiation of ASC, as cells 
gradually recover basal morphology and phenotype within 48-72 hrs of culture with 
basal medium (Figs. 4I, J). Proliferation assay at 72 hrs shows that 7.5 ± 2.5% of ASC 
incorporate BrdU (i.e., half the proliferation rate of ASC in basal conditions); no 
relevant signs of cell death are observed. In addition, ASC multi-lineage differentiation 
potential into adipocytes, osteocytes and chondrocytes is still achievable (data not 
shown). 
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Figure 4. Neural induction medium. In basal condition ASC are spindle-shaped (A, 
hematoxylin staining at optic microscope; B, at scanning electron microscopy). 
Immuno-peroxidase for PMP-22 (C) and GFAP (D) on BM-MSC reveals low levels of 
expression in basal conditions. Dramatic changes after the exposure to neural 
differentiation medium in terms of morphology (E–H) and phenotype (E1–H1) are 
observed on ASC; the majority of ASC assumed an astrocytic/neuronal morphology (E–
G) with bi- and tripolar shape with primary and secondary processes at scanning 
electron microscopy and intense immunoreactivity for PMP-22 (E1), GFAP (F1) and 
Neu-N (G1). About 15–20% of ASC displays oligodendroglial-like morphology with 
multi-branched, irregular shape (H) and selective up-regulation of Gal-C (H1). ASC 
regain their basal morphology (I) and faint immunoreactivity for GFAP (J) 72 h after 
removal of neural induction medium. Background immunostaining obtains with the 
omission of primary antibody on ASC (K) stimulated with neural chemical induction. 
Scale bar: 10 µm. 
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NEURAL DIFFERENTIATION: PROLONGED NEURAL DIFFERENTATION 
As already reported for BM-MSC (Hermann et al, 2004), in the presence of EGF and 
bFGF, ASC form spherical, floating aggregates within 2-5 days (Figs. 5A, B), which 
express nestin, Neu-N, and MAP-2 (Fig. 5C), but not the glial markers Gal-C, GFAP 
and S-100 (Fig. 5D) as well as CD105 (data non shown). The cells can be dissociated 
and culturing in the same media, forming no more than third-passage sphere. The 
neurospheres are then dissociated and single cells cultured in presence of BDNF and 
RA (neuronal induction). Two populations are clearly distinguishable based on 
morphological and immunophenotypical criteria; about half (56.81 ± 2.26%) of ASC 
shows the characteristic neuronal morphology with contracted cytoplasm, condensed 
nucleus and protrusion of two or three cellular processes as shown by electronic 
microscopy (Fig. 5E). By immunocytochemistry, these cells express nestin (Fig. 5F) 
and the neuronal markers MAP-2 and Neu-N (Figs. 5G, H). A very low proportion of 
these cells (about 1%) expresses also TH and α subunit GABA-A receptor (Figs. 5I, J), 
while we fail to detect immunoreactivity for the sodium channel. Interestingly, no signal 
for the glial markers S-100, GFAP, Gal-C is observed (Fig. 5K). The remaining ASC 
show no apparent response to the differentiation protocol and remain large and flat, with 
abundant cytoplasm and do not expressed any neuronal markers. Morphological and 
immunophenotypical changes suggestive of neuronal differentiation persist for at least 
seven days after the removal of differentiation medium (Figs. 5L, M). Exposure to the 
differentiation medium greatly reduces the proliferation rate of ASC. In fact, while 5 ± 
1.5% of MAP-2– ASC with basal morphology is BrdU+ (as compared to 7.5 ± 2.5% of 
untreated cells) (Figs. 6A, B), none of the ASC with neuronal morphology and MAP-2 
staining show incorporation of BrdU (Figs. 6C, D). 
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Figure 5. Morphology and phenotype of ASC subjected to neuronal differentiation. 
Treatment with EGF and bFGF induces the formation of floating aggregates (A, B), 
formed by MAP-2-positive (C), GFAP-negative (D) elements. After 28 days exposure 
to RA/BDNF, ASC exhibit contracted cytoplasm and long processes at scanning 
electron microscope (E), expressed nestin (F) and the neuronal markers MAP-2 (G) and 
NeuN (H). A small portion of the differentiated ASC express TH (I) and α subunit of 
GABA-A receptor (J), but not the glial marker GFAP (K). Morphological and 
phenotypical changes persist for at least 7 days after the replacement basal medium, 
with expression of nestin (L) and MAP-2 (M). Scale bars: 100 µm (A), 50 µm (B-M). 
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Figure 6. Proliferation after neuronal differentiation: the group of ASC not reacting to 
the induction maintain basal morphology and are BrdU+ (A, B), in contrast with ASC 
with neuronal morphology and MAP-2 staining, which do not incorporate BrdU (C, D). 
Scale bar: 50 µm.  
 
The formation of spherical, floating aggregates before the treatment with BDNF/RA 
is fundamental to obtain neuronal differentiation: in the absence of this step, ASC 
subjected to the differentiation protocol continue to proliferate and maintain the basal 
biological features (data not shown).  
 
NEURAL DIFFERENTIATION: ELECTROPHYSIOLOGY 
We evaluate electrophysiological properties in basal condition and after prolonged 
neuronal differentiation using the patch clamp technique in whole-cell configuration. 
Focusing on treated ASC with neuronal morphology, we estimate the membrane 
potential under current-clamp conditions and the presence of voltage-gated channels in 
whole-cell voltage-clamp experiments. The resting membrane potential of ASC with 
neuronal morphology (−59.75 ± 5.41 mV, n = 12) is significantly more negative than 
that of basal ASC (−33.54 ± 3.1 mV, n = 26; p = 0.001) (Fig. 7). Although not 
statistically different, also the mean value of membrane capacitance for differentiated 
ASC is lower (62.70 ± 9.67 pF, n = 10) than basal ASC (87.5 ± 9.51 pF, n = 28). A 
large outward current is isolated after blockage of inward currents with TTX.  
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Figure 7. Resting membrane potential of ASC subjected to neuronal differentiation. 
Values of resting membrane potential of ASC recorded in basal conditions (grey) and at 
28th day after exposure to neuronal differentiation protocol (light grey).  
 
Depolarising pulses ranging from −50 to +40 mV in 10 mV increments from the 
holding potentials of −70 mV evoke a family of non-inactivating currents (Figs. 8A, B), 
significantly larger in differentiated ASC as compared to basal condition: at + 40 mV 
the mean amplitudes are 522.86 ± 117 pA (n = 10) in differentiated cells vs 223.34 ± 
37.55 pA (n = 19) in basal cells (p = 0.005) (Fig. 8C). Their selective block by TEA 
indicates that these currents are carried by potassium ions. Differentiated ASC also 
exhibit a prominent inward current (Fig. 8D), which is virtually absent on basal cells. 
This is isolated by equimolar ion substitution of intracellular K+ with Cs+, and is 
evoked by voltage steps ranging from −50 to +40 mV after a complete removal of 
inactivation with a 200 ms step at −120 mV. At 0 mV the mean peak amplitude is 
−185.09 ± 4.65 pA (n = 7) in differentiated cells vs 4.65 ± 4.65 pA, n = 28 in basal cells 
(Fig. 8F). For their fast inactivation and their sensitivity to TTX these currents are 
definitely mediated by classical voltage-dependent sodium channels. The kinetic of the 
sodium current is investigated in detail. The development of inactivation is studied with 
a series of depolarising steps to the fixed potential of 0 mV after 180 ms conditioning 
pulses between −120 mV and −40 mV (Figs. 8G, H).  
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Figure 8. Electrophysiological features of ASC subjected to neuronal differentiation. 
Activation of potassium currents evoked by depolarizing pulses ranging between −50 
and +40 mV and the corresponding current-voltage relationship in ASC with neuronal 
morphology (A, B). Voltage-clamp reveals a tendency for higher outward currents in 
differentiated ASC than in basal ones (C). Activation of sodium currents evoked by 
increasing depolarizing pulses as indicated in the inset and the corresponding current-
voltage relationship in ASC with neuronal morphology (D, E). ASC with neuronal 
morphology exhibit inward currents significantly higher than basal cells (F). 
Inactivation of the sodium channels in ASC with neuronal morphology, obtained 
following the protocol shown in the inset. The corresponding current-voltage 
relationship, showing the peak amplitudes at the fixed test potential of 0 mV as a 
function of the conditioning pulse, has a midpoint centered at −57.7 mV (G, H). 
Removal of inactivation of the sodium current at −100 mV. Two pulses at 0 mV (inset) 
are separated by a variable delay to allow removal of inactivation, occurring in this case 
with a time constant of 2.0 ms (I). 
 
The half-inactivation is at the potential of −57.7 mV and the time constant for the 
development of inactivation is 2.46 ± 0.13 ms at 0 mV (n = 7). The removal of 
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inactivation is studied using the protocol shown in the inset of Fig. 8I: two consecutive 
depolarizing pulses to 0 mV from different holding potentials (−100 mV for the case 
represented in Fig. 8I) are separated by an interval of variable length. The longer is the 
time spent at the holding potential between the two steps, the larger is the removal of 
inactivation and the amplitude of the current in response to the second depolarizing 
step; the time constant for the removal of inactivation is 2.0 ms at −100 mV. 
To test for the presence of functional receptors, cells are maintained at a holding 
potential of −40 mV. Under these conditions, both glutamate and GABA fail to induce a 
current (data not shown). 
 
ASC SUPPORT NEURITE OUTGROWTH IN VITRO 
In addition to neurophysological features, we evaluated another biological parameter 
characteristic of neuronal commitment, i.e. the presence and the modulation by ASC-
CM of neurite outgrowth.  
 
Figure 9. The percentuage of SH-SY5Y exhibiting the neurite after 48 hrs of culture in 
basal (grey), ASC-CM (horizontal filling) or fibroblast-CM (vertical filling) (A). An 
example of neurite-positve cells after ASC-CM culture, staining with βIII tubulin 
(green) and nuclear DAPI (blue) (B). Scale bar: 50 µm. 
 
For this purpose, we used the human neuroblastoma SH-SY5Y cell model to study 
neuronal response in vitro (Sancivens et al, 2006). We found that ASC-CM increased 
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the neurite outgrowth in SH-SH5Y (7.9 ± 1.9%) after 48 hrs of culture, as compared to 
fibroblast-CM (5.4 ± 0.4%) and basal medium (3.5 ± 0.5%) (Figs. 9A, B). 
 
PROTECTION AGAINST OXIDATIVE STRESS 
We then assessed whether ASC may exert a neuroprotective effect, by using an 
oxidative-stressed neuron model in vitro (Haque et al, 2003). SH-SY5Y cells are 
exposed to H2O2, the main endogenous ROS which induces cytotoxic effect. H2O2 is 
added to basal medium or to ASC-CM (1:1) for 24 hrs. The cell viability is reduced 
after oxidative stress in basal group compared to ASC-CM group (92.1 ± 5.7% 
compared to 102 ± 2.9%). The protective effect was not evident at higher concentration 
(200 µM) of H2O2 (Fig. 10). 
 
        
Figure 10. Cell viability assay in SH-SY5Y in response to H2O2, with or without ASC-
CM. SH SY5Y cells are incubated with 100 µM and 200 µM H2O2 for 24 hrs. The 
control cells (grey, unbroken line) are incubated in basal media (10% FBS/DMEM). 
The ASC-CM cells (black, dotted line) are culturing for 24 hrs, as long as the interval of 
H2O2 exposure. The MTT assay is performed. 
 
Then we evaluated whether the increased number of viable cells in the group treated 
with ASC-CM and 100 µM H2O2 was related to a decreased of apoptotic rate. SH-SY5Y 
are grown in the presence of 100 µM H2O2 in ASC-CM, fibroblast-CM or basal medium 
for 48 hrs. The presence of ASC-CM indeed protected SH-SY5Y results from 
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apoptosis, with a fold increase of caspase 3+ cells of 1.89 ± 1.09% (while fibroblast-CM 
was 3.31 ± 0.46% and basal 2.86 ± 1.21%) (Figs. 11, 12). 
 
 
Figure 11. SH-SY5Y apoptosis evaluation after culturing in ASC-CM (horizontal 
filling) and fibroblast-CM (vertical filling) during 24 hrs 100 µM H2O2 exposition. Cell 
in basal media (grey). The caspase 3+ cells are reported as the average of cell positive 
for one field. Each value represents mean ± SD of three independent experiments.  
 
 
 
 
Figure 12. SH-SY5Y apoptosis evaluation after H2O2 exposition, culturing in basal 
medium (A), ASC-CM (B) and fibroblast-CM (C) for 24 hrs. The caspase 3 stains 
green; DAPI (blue) marks the nucleus. Scale bar: 50 µm. 
 
 
PRODUCTION OF NEUROTROPHINS BY ASC 
We next sought to determine whether BDNF, bFGF, CNTF and PDGF-AB are 
produced by human ASC and if this can explain the diverse neuroprotective effect from 
fibroblasts. ELISA assay in supernatants demonstrated significant amounts of BDNF 
secreted by ASC, but not from fibroblast (64.7 ± 10.58 pg/ml vs 0 pg/ml). Low amounts 
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of bFGF are synthesized by both cells types (Fig. 13), while CNTF and PDGF-AB are 
absent.  
      
Figure 13. BNDF, bFGF, CNTF and PDGF-AB are quantified by ELISA, and reported 
as concentration (pg/ml) in ASC (horizontal filling) and fibroblast (vertical filling) 
supernatants.  
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DISCUSSION 
 
This study raises from the interest of evaluating the ability of human ASC to 
differentiate in neuronal cells. Later on, we investigated their potential to exert neuro-
protection. The source of these cells make them further attractive because they are 
easily obtained in large amount by human fat with liposuction and they are highly 
proliferative in culture (our data; Dennis and Charbord, 2002; Zuk et al, 2002; 
Romanov et al, 2005; Katz et al, 2005; Lee et al, 2004; Kern et al, 2006; Strem et al, 
2005).   
Although some authors have already studied the neural differentiation from ASC 
(Safford et al, 2004; Kang et al, 2005; Ashiijan et al, 2003), the complete differentiation 
has not been demonstrated; rather, these studies show unspecific neural modification, 
with co-existence of neuronal and glial features. More data are available about ASC 
toward peripheral glial cell (Radke et al, 2009; Xu et al, 2008; Kingham et al, 2007). 
We first applied a chemical induction protocol (Woodbury et al, 2000) on human 
ASC, to consider if they behave similarly to BM-MSC: ASC modify into 3 sub-
populations different for morphology and phenotype: one neuron/astrocytic-like 
expressing neural markers, the second oligodendrocyte-like, selectively reactive for 
Gal-C and the remaining sub-population is undifferentiated. The co-expression of neural 
markers of different lineages in the former group, some atypical immunochemical 
pattern (both cytoplasmic and nuclear staining for Neu-N) and the blunt onset and very 
short-lasting modifications raise doubts about the authentic modification (Krampera et 
al, 2007).  
Our data are quite concordant with studies published from other groups, that 
alternatively report the immunocytochemical or the immunoblot profile (Safford et al, 
2002; Safford et al, 2004; Tholpady et al, 2003). As we mentioned in the introduction, 
44 
 
DMSO/BHA treatment does not activate neural genes in BM-MSC, and it can induce 
very similar morphological change in keratinocytes and fibroblasts as in MSC 
(Woodbury et al, 2000; Lu et al, 2004; Bertani et al, 2005; Neuhuber et al, 2004). In a 
more in-depth probe of changes in the transcriptome (21,000-gene microarray analysis), 
Bertani et al. showed that the stimulation with the BHA/DMSO protocol for 6 hrs and 
48 hrs has little effect on the overall transcription profile of BM-MSC cells. The 
treatment also does not significantly change the levels of certain neural-associated 
markers already expressed by MSC (Bertani et al, 2005). These findings suggest that 
the morphological changes resembling neural differentiation observed with the chemical 
induction protocol can largely result from a fast-onset cellular response to chemical 
toxicity, and not from a differentiation program.  
Then we decided to use a medium more similar to the natural CNS environment, 
considering either some of the fundamental molecules involved in neural survival and 
plasticity, following a previously described protocol (Hermann et al, 2004).  
RA plays a key role in neurogenesis during the embryogenesis and later on during 
the remodeling following a brain insult; moreover, it induces the expression of the 
BDNF receptor (Glaser and Brustle, 2005). BDNF regulates the neuronal proliferation, 
migration and maturation; in addition it is involved in translating the activity signal into 
synaptic plasticity changes. Such neurotrophin is produced by both neural elements and 
endothelial cells of CNS, dependently to environment insults. MSC exhibit the specific 
receptors and are able to synthesize BDNF (Zhao et al, 2004; Tapia-Arancibia et al, 
2004; Crigler et al, 2006). Neural induction media using different combination of RA 
and BDNF with or without other agents have been experimented on BM-MSC by 
several groups (Sanchez-Ramos et al, 2000; Padovan et al, 2003; Zhao et al, 2004; 
Dezawa et al, 2004; Egusa et al, 2005; Cho et al, 2005; Kohyama et al, 2001; Jiang et 
al, 2002; Jiang et al, 2003; Long et al, 2005; Kondo et al, 2005), but only few studies 
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have been performed on ASC (Kang et al, 2004; Romanov et al, 2005). In particular, 
RA/BDNF do not dramatically modify BM-MSC phenotype after 14 days (Sanchez-
Ramos et al, 2000), but the transfection of the BDNF gene in BM-MSC and the 
following treatment with RA induce non selective neural markers and, more 
interestingly, the formation of the voltage-dependent K+/Ca2+ channel (Zhao et al, 
2004).  
Our prolonged neuronal protocol derived from the observation that neurosphere 
medium, traditionally used for NSC (Reynolds and Weiss, 1992), can prompt also MSC 
toward very early neural commitment. Hermann and colleagues used sequentially 
neurosphere medium and RA/BDNF: the BM-MSC acquire neuronal morphology and 
phenotype, but there are no electrophysiological confirmation of such transformation 
(Hermann et al, 2004). Another group employed BDNF after the neurosphere-step to 
prime ASC, obtaining the concomitant expression of neuronal and glial markers at 
transcriptional and protein level (Kang et al, 2004).  
To our knowledge, this is the first demonstration that human ASC, submitted to two-
step protocol (neurosphere medium and consecutive RA/BDNF neuronal induction) 
show selectively early neuronal behavior in vitro. ASC in culture with EGF and bFGF 
aggregate in floating neurosphere-like, morphologically very similar to NSC 
neurosphere. ASC strongly exhibit nestin and MAP-2, as previously reported (Bunnell 
et al, 2006), suggesting that this step represents the neural pre-commitment necessary to 
obtain the response to the following induction medium. RA and BDNF medium induces 
a high proportion (57%) of ASC to acquire a neuronal phenotype: they are PSA-NCAM, 
Neu-N, MAP-2 positive and lack the expression of glial markers as GFAP and S-100, 
remaining weakly positive for nestin. In addition, they display a number of features of 
more mature neuronal phenotype, with expression of TH and α subunit of GABA-A 
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receptor, but not of Na+ channel. These data confirm a previous study on the 
neurotransmitter enzyme profile of ASC (Safford et al, 2004). 
In line with this immunophenotype, the electrophysiological analysis confirms the 
early selective neuronal differentiation: ASC with neuronal features displayed resting 
membrane potential close to −60 mV, outward currents blocked by TEA, suggestive of 
delayed-rectifier type K+ currents, as well as voltage-dependent Na+ currents selectively 
inhibited by TTX. We detected these features exclusively in the ASC with neuronal 
morphology and phenotype, and not in basal conditions or in ASC not responding to 
neural differentiating stimuli. Although K+ currents are also related to proliferation and 
migration in other type of cells (Fantozzi et al, 2006), the presence of Na+ currents and 
the negative resting membrane potential are highly neuronal specific. Despite these 
features, the amplitude of the current is not enough to produce an action potential or to 
react to GABA or glutamate. These results are strongly meaningful, comparing to basal 
ASC features, that show resting membrane potential around –30 mV, very low K+ 
current amplitude and virtually absent Na+ currents. Basal electrophysiological ASC 
properties are not fully concordant with a previous report that describe up to 70% basal 
ASC with different K+ currents and 7% with Na+ currents, analyzing third passage cells 
(Bai et al, 2007). The absence of immunoreactivity for Na+ channel in differentiated 
ASC showing inward currents sensitive to TTX by patch-clamp is probably related to 
the different sensitivity between these two procedures, as already described (Dezawa et 
al, 2004). On the other hand, the induction of Na+ current has been already described in 
BM-MSC treated with RA and/or other growth factors (Hung et al., 2002; Egusa et al., 
2005; Dezawa et al, 2004; Cho et al, 2005; Tropel et al, 2006). The extent of the 
current was otherwise significant only after co-culture of BM-MSC with fetal astrocyte 
or cerebellar granule (Jiang et al, 2003; Wislet-Gendebien et al, 2005b) or Notch 
transfection followed by CNTF, NGF and BDNF treatment (Dezawa et al, 2004) or 
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very high concentration of RA (Cho et al, 2005). Nowadays the unique 
electrophysiological data regarding the neural ASC differentiation is related to the 
delayed-rectifier type K+ currents induced by IBMX and indomethacin for 14 days 
(Ashjian et al, 2003). 
The incomplete neuronal differentiation observed in our and other studies suggests 
that ASC might exert their therapeutic efficacy via mechanisms alternative to cell-
replacement, as already proposed by BM-MSC. We and other authors have very 
recently reported that ASC in vivo model can not differentiate in neural cells 
(Constantin et al, 2009; Kim et al, 2007), in contrast with few others documenting the 
early neural differentiation in CNS (Kim et al, 2009; Lee et al, 2009). Noteworthy, 
irrespective of the exact cellular mechanism, in all these studies MSC application was 
clinically beneficial.  
An alternative explanation for this beneficial effect involves the ability of MSC to 
produce a wide range of potentially neuroprotective factors or by their anti-oxidant 
action (Lanza et al, 2009; Crigler et al, 2006; Wilkins et al. 2009; Hokari et al, 2008; 
Parr et al, 2007). It is conceivable that the final therapeutic effect comes from the 
complex interaction between the transplanted cell and the environment and that multiple 
mechanisms are involved. In this regard, we evaluated the ability of ASC to protect 
neuron using an in vitro model of oxidative stress, in which a neuroblastoma cell line is 
exposed to H2O2 (Sancivens et al, 2006). Neuroblastoma cell lines are a classic model to 
study neuronal biological responses to different type of insults. H2O2 is the main 
endogenous ROS generated by several enzymes as peroxide dismutase, glucose oxidase 
and monoamine oxidase. The cytotoxic effect of H2O2 is thought to be caused by 
hydroxyl radicals generated from iron-catalyzed reactions, causing subsequent damage 
to DNA, proteins and membrane lipids. In particular, H2O2-induced cell death in 
neuroblastoma cell line involves an apoptotic mechanism dependent on caspase 3 and 
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calpain activation, mediated by AKT and JNK activity (Sebastià et al, 2006; Sancivens 
et al, 2006). The final effect of apoptosis in neural cells is mediated by p53 pathway 
(McNeill-Blue et al, 2006). 
We tested the protective effect of ASC-CM on neuroblastoma, as compared to basal 
and fibroblast-CM. After 24 hrs H2O2 exposition, the number of neuroblastoma cells 
was significantly reduced, regardless H2O2 concentration. Interestingly, the ASC-CM 
reverted the number of cells exposed to 100 µM of H2O2 to the basal levels, thus 
displaying a true protective effect. We then investigated the death/survival pathway 
involved in neuro-protection against H2O2 stress, finding that ASC-CM exhibit anti-
apoptotic function with reduction of caspase 3+ cells, as compared to fibroblast-CM and 
basal media. Although the high proliferation rate of the neuroblastoma cell line does not 
reproduce the biology of neuronal cells, the data about the anti-apoptotic effect of ASC-
CM are quite intriguing. In fact, neuronal apoptosis is critical for the pathogenesis of 
neurological diseases (Prunell and Troy, 2004); and this process as well as neuronal 
proliferation and survival is highly regulated by neurotrophic factors, which are also 
particularly important in the pathogenesis of neurodegenerative disorders.  
Such results are concordant with a very recent study (Lee et al, 2009), supporting the 
role of secreted factors by human and rat ASC (Wei et al, 2009a; Wei et al, 2009b) and 
human BM-MSC (Hokari et al, 2008; Wilkins et al, 2009; Kemp et al, 2010). An 
indirect evidence of the anti-oxidant effect by ASC is remarked in therapeutic model of 
EAE reported by our group (Constantin et al, 2009): 72 days after systemic ASC 
injection in EAE mice, spinal cord neurons show significantly lower apoptosis (caspase 
3+ cells) than the control (13.28 ± 1.41/mm2 vs 1.95 ± 0.82/mm2). Such data are 
concordant with those from other groups, which reported the reduction of apoptotic 
neuron after ASC treatment in other animal models (Kim et al, 2007; Lee et al, 2009; 
Wei et al, 2009a). Similarly, other groups reported the modulation of the endogenous 
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anti-oxidant enzyme activity by MSC in vivo (Lanza et al, 2009; Lee et al, 2009), in 
addition to their ability to release growth factors. To assess if such oxidative stress is 
detrimental for ASC, we treated the cells at the same conditions of neuroblastoma, and 
we report no increase of the apoptosis. From these data, we suppose that ASC can 
survive easier in neural stressful environment than the neuron, although the MSC long-
term survival is variable in different animal models (Kim et al, 2007; Lee et al, 2003; 
Gerdoni et al, 2007; Zhang et al, 2009).  
We then test the potential effect of secreted molecules by ASC to induce an early 
neural differentiation on neuroblastoma cells. Neurite formation of neuroblastoma is 
significantly influenced by ASC-CM (as compared to fibroblast-CM or basal medium), 
in line with other studies on BM-MSC; in particular, human BM-MSC can induce 
neurite outgrowth on neuroblastoma cells (either RA-induced or not) (Crigler et al, 
2006; Croft and Przyborski, 2009). Noteworthy, the only study with ASC reported no 
difference between culturing neuroblastoglioma with ASC-CM or not (Kingham et al, 
2007). It is reasonable that such discrepancy may be related to different methodological 
approaches. We show that human ASC, but not fibroblasts secrete high amounts of 
BDNF, as reported for human BM-MSC (Crigler et al, 2006; Neuhuber et al, 2005). 
Surprisingly, we detected higher level of BDNF compared to what mostly reported by 
literature (Neuhuber et al, 2005; Jiang et al, 2010; Crigler et al, 2006; Wilkins et al, 
2008; Wei et al, 2009a). Since BDNF receptors are present in neuron and in 
neuroblastoma (Tapia-Arancibia et al, 2004; Brodeur et al, 2009), we hypothesize that 
the protective action of ASC may be partially mediated by BDNF (Crigler et al, 2006; 
Wilkins et al, 2008). In addition to BDNF, moderate levels of bFGF, but not CNTF and 
PDGF-AB were detected in supernatants from ASC. In addition to the paracrine effect 
of growth factors, the communication with the resident cells and the cell-cell contact 
may strength the neuroprotective effect of MSC in vivo.  
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Taken together, our results suggest that neuronal differentiation of a proportion of 
ASC is possible, though incomplete and with low-efficiency in vitro. The full neuronal 
differentiation of MSC in vitro remains an intriguing challenge in the field of stem cells 
and CNS repair, particularly for neurodegenerative diseases. As a matter of fact, 
transplantation of MSC may promote CNS repair through the stimulation of endogenous 
neural precursors and via intrinsic neuroprotective bystander capacities; undifferentiated 
SC can release, at the site of tissue damage, a milieu of neuroprotective and 
immunomodulatory molecules, whose release is temporally and spatially orchestrated 
by environmental needs (Constantin et al, 2009). Since these molecules, acting in a 
paracrine fashion, are pleiotropic and redundant and ‘constitutively’ secreted by SC – 
thus representing a sort of stem cell signature – we can easily explain data showing that 
stem cells other than NSC, with very low capabilities of neural (trans) differentiation 
may efficiently promote CNS repair. 
The powerful aspect of ASC application is the possibility of autologous 
transplantation, avoiding any risk of rejection, although it is debated if MSC can be 
modified in human carrying genetic neurological diseases (Boucheire et al, 2008; 
Ferrero et al, 2008). 
In 2008 the report of the induced Pluripotent Stem Cell (iPSC) has been the 
‘breakthrough of the year’ (Vogel, 2008). iPSC are pluripotent cell obtained by the 
reprogramming of murine skin fibroblast by retroviral expression of four transcription 
factors (Oct4, Sox2, Klf4 and c-Myc), that are able to give rise to all three germ layers 
(Takahashi and Yamanaka, 2006). The generation of iPSC would potentially allow for a 
source of cellular therapy for auto-transplantation and provide ethically acceptable 
routes to derive patient-specific stem cells. But the concern about the risk of cancer 
remains (Okita et al, 2007), due to the use of integrating viruses which, for their 
oncogenic transgenes and insertional mutagenesis, are potentially tumorigenic. 
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Recently, alternative techniques for the derivation of iPSC have been developed, 
including the use of viruses other than retrovirus, non-integrating viruses, episomal 
expression systems or direct delivery of the reprogramming factors as bioactive 
proteins.  
Wernig et al. have fascinatingly opened the door to specific neural application: iPSC 
from murine fibroblast, transfected with lentivirus with three neural-lineage-specific 
transcription factors can generate (up to 19.5%) functional neurons in vitro, displaying 
trains of action potentials and synapses with ex vivo cortical neuron (Vierbuchen et al, 
2010). The fast conversion in neuron from iPSC can represent a promising strategy to 
get neural replacement, avoiding the tumorigenic pluripotent stem cells. Despite rapid 
progress in the field of reprogramming, several obstacles need to be overcome before 
iPSC can be considered in a clinical context. First, standardized protocols have to be 
developed. Second, genetic and epigenetic instability will also be highly relevant for the 
use of iPSC. Third, the optimum source of somatic cells used for reprogramming has 
not yet been identified. With these considerations in mind, we believe that cell therapy 
with iPSC will represent the new frontier for the regenerative medicine. 
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ABBREVIATIONS 
 
ASC         Adipose-derived Stem Cell 
ASC-CM  ASC-Condition Media  
bFGF        basal Fibroblast Growth  
    Factor   
BM        Bone Marrow 
BME         βmercaptoetanol 
BM-MSC  Bone Marrow-MSC 
BHA         Butylatedhydroxyanisole  
CNS         Central Nervous System 
CNTF        Ciliary Neurotrophic Factor  
dbcAMP  dibutiril cAMP  
DMEM     Dulbecco’s Modified Eagle’s  
        Medium 
DMSO      Dimethyl sulfoxide 
EAE         Experimental Autoimmune  
        Encephalomyelitis 
EGF         Epidermal Growth Factor  
ESC         Embryonic Stem cell 
FBS         Fetal Bovine Serum  
GFAP        Glial Fibrillary Acidic Protein  
HGF         Hepatocyte Growth Factor  
HSC         Hematopoietic Stem cell 
IGF1        Insulin Growth Factor 1  
IBMX        Isobutylmethylxanthine  
iPSC        induced Pluripotent Stem Cell  
ISCT                International Society for  
               Cellular Therapy 
mAb                monoclonal antibody 
MAP-2             Microtubule- 
              Associated Protein-2 
MSC   Mesenchymal Stem Cell 
NB  Neurobasal 
Neu-N  Neuronal Nuclear antigen  
NGF  Nerve Growth Factor  
NSC   Neural Stem Cell 
PD   Parkinson Disease  
RNS   Reactive Nitroxide 
Species 
ROS   Reactive Oxidative  
  Species 
RT-PCR    Reverse transcription- 
  Polymerase Chain  
   Reaction   
SCI   Spinal Cord Injury 
TEA  Tetraethylammonium 
TH  Tyrosine Hydroxylase  
TTX  Tetrodotoxin 
VEGF  Vascular Endothelial  
  Growth Factor  
 
 
